Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of atherosclerotic cardiovascular disease (ASCVD) in the UAE: Results of the PACT-MEA-UAE cohort
Authors' conclusion
Physicians followed international guidelines, considering patient history, drug efficacy, and HbA1c levels for diabetes and ASCVD risks. In UAE, <50 % of at-risk individuals with T2D met ESC targets. Cardioprotective medication use was higher in UAE.
Study context
- Population
- People with T2D with established ASCVD or high ASCVD risk, Middle East and Africa (PACT-MEA)385 physicians surveyed
- Participants
- 3,726 people
- Exposure
- UAE vs broader MEA region participants
- UAEn = 542
- Outcome
- Achievement of 2021 ESC guideline T2D targets
Methodological detailsphysician survey, chart review
- Physician survey
- Chart review
Main finding
As reported in the abstract
- UAE
- HbA1c target achieved 45 % vs. 37 %
- UAE
- BP target achieved 41 % vs. 30 %
- UAE
- LDL target achieved 36 % vs. 30 %
- UAE
- BMI <25 kg/m² 20 % vs. 15 %
- UAE
- SGLT2i use 63 % vs. 37 %
- UAE
- GLP-1 RA use 22 % vs. 13 %
- Participants meeting all ESC-recommended T2D targets
- 0
Observational data: associations, not effects.
Further findings
ASCVD risk category among UAE participants
%
- High risk
- 62.7
- Very high risk
- 37.1
Physician survey
- Most physicians adhered to international guidelines
Original publication
Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: Results of the PACT-MEA-UAE cohort. Diabetes Res Clin Pract. Published 3 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →